Company Spotlight

Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Company Spotlight
Hereditary Angioedema Therapeutic Market Report and Forecast 2025-2034
As per the analysis by Expert Market Research, the global hereditary angioedema therapeutic market was valued at USD 3.16 billion in 2024 and is projected to grow at a CAGR of 7.80% from 2025 to 2034, reaching approximately USD 6.70 billion by 2034.
Recurrent episodes of significant swelling are a defining feature of the illness known as hereditary angioedema (angioedema). The limbs, face, digestive system, and airway are the body parts that experience swelling the most frequently. An attack will likely start with a small amount of stress or trauma, but swelling can frequently happen without a clear cause.
The hereditary angioedema therapeutic market growth will likely be fuelled owing to an increase in the knowledge of hereditary angioedema and the expansion of the healthcare sector across emerging economies. Appendicitis, gastrointestinal issues, and other non-allergic angioedema illnesses are sometimes misdiagnosed in hereditary angioedema patients. A significant patient population with severe medical demands is formed by a small number of patients who were incorrectly diagnosed with the illness. In the upcoming years, this is anticipated to be a major market driver for therapeutics for hereditary angioedema.
The growing research and development activities and the investment in orphan drug development will further boost the growth of the hereditary angioedema therapeutic market. Moreover, an increasing attention on the evolving novel therapeutics is expected to further provide potential opportunities for the market growth globally in the upcoming years. The other factors aiding the market growth include rising population and increasing disposable income.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Headquarters: | Tokyo, Japan |
Establishment: | 1781 |
Website: | https://www.takeda.com/en-in/ |
Takeda is a multinational biopharmaceutical company committed to using patient-centred and ethical research and development to improve the health and future of people everywhere. The company has presence in about 80 nations, with the United States and Japan holding the first and third-largest pharmaceutical marketplaces in the world, respectively.
Headquarters: | North Carolina, United States |
Establishment: | 1986 |
Website: | https://www.biocryst.com/ |
A group of dedicated individuals lead BioCryst Pharmaceuticals, Inc., which works to provide novel treatments for patients with rare diseases. The company has experience in medication research, clinical development, and regulatory affairs. It is involved in developing clinical projects and producing new compounds from its own discovery engine. It focuses on developing medications for rare diseases, where patients' needs are still largely unmet.
Headquarters: | California, United States |
Establishment: | 1989 |
Website: | https://www.ionispharma.com/ |
Ionis Pharmaceuticals, Inc. developed the world's first and only RNA-targeted therapy that is licenced for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. It also has the first and only treatment for children and adults with spinal muscular atrophy. The business's medication discovery platform has provided patients with unmet needs with meaningful solutions.
Headquarters: | Netherlands |
Establishment: | 1988 |
Website: | https://www.pharming.com/ |
Pharming Group N.V., a multinational biopharmaceutical business develops precision medicines and novel protein replacement therapies for the treatment of uncommon diseases and unmet medical needs. Recombinant human C1 esterase inhibitor RUCONEST® (conestat alfa), the flagship product of Pharming, has been approved for the treatment of acute attacks of hereditary angioedema (‘HAE’) in individuals in Europe, the United States, Israel, and South Korea. In other regions where it does not yet have marketing authorisation, the product is offered on a named-patient basis.
Headquarters: | Melbourne, Australia |
Establishment: | 1916 |
Website: | https://www.csl.com/ |
A biopharmaceutical business called CSL Limited promises to save lives of people who are stricken with chronic medical conditions. The company offers the broadest range of premium plasma-derived and recombinant medications in the market.
Headquarters: | New York, United States |
Establishment: | 2015 |
Website: | http://attunepharma.com/ |
Private biotechnology business Attune Pharmaceuticals, Inc. focuses on the development and discovery of new, orally delivered small-molecule medicines for the treatment of rare disorders.
Dr. Jagriti Punia
Healthcare market research analyst with 2+ years of experience in market research and competitive intelligence, specializing in life sciences, cardiovascular, medical imaging, and diabetes sectors. Expertise includes conducting primary and secondary research, analyzing industry trends, and evaluating market dynamics. Skilled in both qualitative and quantitative analysis, data visualization, and report writing to support strategic decision-making. Additionally, has experience in social research projects, assessing healthcare policies, community health initiatives, and public health trends to provide valuable insights for stakeholders.
Latest Updates on Thriving Economically in a World of Constant Innovation
AI is transforming the pharmaceutical and MedTech sectors by accelerating drug discovery, enhancing ...
Discover the World Health Organization’s new comprehensive guidelines to fight meningitis. This ar...
President Trump’s new executive order targets high U.S. drug prices by requiring pharmaceutical co...
Top 10 Companies in the Neuroendoscopy Devices Market in 2025 - Intuitive Surgical Inc., Stryker Ind...
A subscription-based dashboard by Expert Market Research, offering all-encompassing market intelligence.
A subscription-based dashboard by Expert Market Research, offering all-encompassing market intelligence.
A subscription-based dashboard by Expert Market Research, offering all-encompassing market intelligence.
To place an order through our website, select the license type mentioned on the report details page. Click on the ‘Buy Now’ button and fill in your details. Select your preferred mode of payment after which you will be redirected to the selected payment gateway. Follow the steps and proceed to checkout.
www.expertmarketresearch.comEnlisting all your requirements and queries along with details that include billing and delivery address and the preferred payment mode. Our customer service representative will revert to you within 24 hours.
[email protected]To place an order through telephone, call our sales team on the following numbers and our customer service representative will help you regarding the same.
+61 291 889 415Please note you will no longer be purchasing within our bundle subscription.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office) +
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia +
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India +
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines +
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom +
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam +
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
This website uses cookies to improve your experience. By clicking “Accept” you are agreeing to our Privacy Policy.
Share